 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- MEDI3506 / AstraZeneca
[VIRTUAL] IL-33 as a Novel Target for the Treatment of Diabetic Kidney Disease () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2001;
Conclusion Upregulation of IL-33 in diabetic kidney, generates localised chronic kidney inflammation through autocrine signalling in GECs and MCs. This data suggest that targeting IL-33 with MEDI3506 arises as a promising therapeutic intervention for DKD, currently in Ph2b trial.
- || tozorakimab (MEDI3506) / AstraZeneca
New P1 trial: Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants (clinicaltrials.gov) - Oct 6, 2021
P1, N=36, Recruiting, Sponsor: AstraZeneca
- || tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - Sep 23, 2021
P2b, N=565, Recruiting, Sponsor: AstraZeneca
This data suggest that targeting IL-33 with MEDI3506 arises as a promising therapeutic intervention for DKD, currently in Ph2b trial. Trial completion date: Oct 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Feb 2023
- || tozorakimab (MEDI3506) / AstraZeneca
Trial primary completion date: FRONTIER-3: Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma (clinicaltrials.gov) - Sep 1, 2021
P2, N=278, Recruiting, Sponsor: AstraZeneca
Trial completion date: Oct 2023 --> Apr 2023 | Trial primary completion date: Sep 2023 --> Feb 2023 Trial primary completion date: Mar 2022 --> Jul 2022
- || tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - Aug 18, 2021
P2b, N=565, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Mar 2022 --> Jul 2022 Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Nov 2022 --> Sep 2023
- || tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - May 11, 2021
P2b, N=565, Recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Nov 2022 --> Sep 2023 Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Jun 2022 --> Sep 2022
- || tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: FRONTIER-4: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (clinicaltrials.gov) - Apr 22, 2021
P2, N=322, Recruiting, Sponsor: AstraZeneca
Trial completion date: Aug 2022 --> Nov 2022 | Trial primary completion date: Jun 2022 --> Sep 2022 Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
- | tozorakimab (MEDI3506) / AstraZeneca
Trial completion date: Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - Mar 21, 2021
P2, N=152, Recruiting, Sponsor: AstraZeneca
Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Nov 2021 --> Feb 2022
- |||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open: FRONTIER-4: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (clinicaltrials.gov) - Jan 13, 2021
P2, N=322, Recruiting, Sponsor: AstraZeneca
Trial completion date: Nov 2021 --> Feb 2022 Not yet recruiting --> Recruiting
- ||||| tozorakimab (MEDI3506) / AstraZeneca
New P2 trial: FRONTIER-4: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis (clinicaltrials.gov) - Nov 15, 2020
P2, N=322, Not yet recruiting, Sponsor: AstraZeneca
- |||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - Oct 4, 2020
P2b, N=565, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Phase classification: P2a --> P2b | N=168 --> 565 | Trial completion date: Oct 2021 --> Aug 2022 | Trial primary completion date: Oct 2021 --> Jun 2022
- ||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open: Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - Oct 1, 2020
P2, N=152, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Recruiting | Phase classification: P2a --> P2b | N=168 --> 565 | Trial completion date: Oct 2021 --> Aug 2022 | Trial primary completion date: Oct 2021 --> Jun 2022 Active, not recruiting --> Recruiting
- ||||| tozorakimab (MEDI3506) / AstraZeneca
New P2 trial: FRONTIER-3: Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma (clinicaltrials.gov) - Sep 29, 2020
P2, N=228, Recruiting, Sponsor: AstraZeneca
- || Clinical, P2 data, Clinical Trial,Phase II, Journal: ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. (Pubmed Central) - Aug 19, 2020
P2
The full protocol (Master Protocol with each of the candidate sub-protocols) is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- || tozorakimab (MEDI3506) / AstraZeneca
Enrollment closed, Trial completion date, Trial primary completion date: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - May 10, 2020
P2a, N=168, Active, not recruiting, Sponsor: AstraZeneca
In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
- | New P2 trial: A Phase 2 Study for the Treatment of COVID 19 in Hospitalised Patients (EUDRACT) - Apr 30, 2020
P2, N=825, Ongoing, Sponsor: University Hospital Southampton NHS Foundation Trust
- || tozorakimab (MEDI3506) / AstraZeneca
Enrollment closed: Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - Apr 19, 2020
P2, N=152, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Oct 2021 Recruiting --> Active, not recruiting
- ||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment change: Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - Mar 10, 2020
P2, N=152, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting N=108 --> 152
- |||| tozorakimab (MEDI3506) / AstraZeneca
New P2 trial: Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - Dec 25, 2019
P2, N=108, Recruiting, Sponsor: AstraZeneca
- ||| tozorakimab (MEDI3506) / AstraZeneca
Trial completion: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - Dec 13, 2019
P1, N=88, Completed, Sponsor: MedImmune LLC
N=108 --> 152 Active, not recruiting --> Completed
- ||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - Dec 3, 2019
P2a, N=168, Recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| tozorakimab (MEDI3506) / AstraZeneca
New P2a trial: A Phase 2b Diabetic Kidney Disease Study (clinicaltrials.gov) - Nov 20, 2019
P2a, N=168, Not yet recruiting, Sponsor: AstraZeneca
- || tozorakimab (MEDI3506) / AstraZeneca
Enrollment closed: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - May 16, 2019
P1, N=88, Active, not recruiting, Sponsor: MedImmune LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - Jul 18, 2018
P1, N=96, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Trial completion date: Mar 2020 --> Dec 2019 | Trial primary completion date: Mar 2020 --> Dec 2019
- || tozorakimab (MEDI3506) / AstraZeneca
Trial completion date, Trial primary completion date: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - May 31, 2018
P1, N=96, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Mar 2020 --> Dec 2019 | Trial primary completion date: Mar 2020 --> Dec 2019 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- ||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - May 2, 2018
P1, N=80, Recruiting, Sponsor: MedImmune LLC
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Suspended --> Recruiting | Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
- | tozorakimab (MEDI3506) / AstraZeneca
Trial suspension: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - Jan 23, 2018
P1, N=80, Suspended, Sponsor: MedImmune LLC
Suspended --> Recruiting | Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Recruiting --> Suspended
- ||| tozorakimab (MEDI3506) / AstraZeneca
Enrollment open: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - Jun 14, 2017
P1, N=80, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ||| tozorakimab (MEDI3506) / AstraZeneca
New P1 trial: Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants (clinicaltrials.gov) - Mar 30, 2017
P1, N=80, Not yet recruiting, Sponsor: MedImmune LLC